Igc pharma reports first quarter fiscal 2026 financial results; company accelerates phase 2 alzheimer's trial

Potomac, maryland / access newswire / august 19, 2025 / igc pharma, inc. ("igc" or the "company") (nyse american:igc), a clinical-stage biotechnology company leveraging ai to develop innovative treatments for alzheimer's disease, reported its financial results for the quarter ended june 30, 2025. highlights in the quarter include: accelerated progress on the company's phase 2 calma trial in alzheimer's disease progress in the development of mint-ad extension of its undrawn $12m credit facility ram mukunda, ceo of igc pharma, commented, "we began fiscal 2026 with solid strategic momentum, advancing multiple programs that we believe position igc for meaningful value creation this fiscal year.
IGC Ratings Summary
IGC Quant Ranking